Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 28, 2024 06:50 ET | Source: Pharvaris N.V.

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

ZUG, Switzerland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat...
August 14, 2024 06:50 ET | Source: Pharvaris N.V.

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

Alignment with regulatory agencies following End-of-Phase 2 meetings for the prophylactic development of deucrictibant; global startup activities of CHAPTER-3, pivotal Phase 3 study of deucrictibant...
June 11, 2024 06:50 ET | Source: Pharvaris N.V.

Pharvaris Announces Annual Meeting of Shareholders

ZUG, Switzerland, June 11, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...
June 04, 2024 06:50 ET | Source: Pharvaris N.V.

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hoursHigh treatment satisfaction of deucrictibant driven by favorable effectiveness subdomain score...
May 13, 2024 06:50 ET | Source: Pharvaris N.V.

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...
May 08, 2024 16:10 ET | Source: Pharvaris N.V.

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant...
April 10, 2024 16:10 ET | Source: Pharvaris N.V.

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of...
April 10, 2024 16:08 ET | Source: Pharvaris N.V.

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...
April 04, 2024 06:50 ET | Source: Pharvaris N.V.

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...
March 18, 2024 06:50 ET | Source: Pharvaris N.V.

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule (PHVS416) for the treatment of HAE attacks ...